The expansion of Biological E.'s vaccine manufacturing facility in Hyderabad was unveiled by the U.S. International Development Finance Corporation and Biological E. Limited on Monday.

This financial support from the US government was announced at the Quad Summit in March 2021.

The Hyderabad facility finalised a U.S. government financing arrangement formalizing USD 50 million to expand the company's capacity to produce COVID-19 vaccines so as to bolster near-term COVID-19 response efforts, as per the press release by the US Mission India. It will also benefit long-term global health in India and throughout the Indo-Pacific region.

Chief Operating Officer, DFC, David Marchick said, "DFC's partnership with Biological E will support capacity for production of more than one billion vaccine doses by the end of 2022 for India and for developing countries around the world."

"Scaling Biological E.'s new facility, which is already producing vaccines, will help close the vaccine gap and save lives in developing countries," DFC chief operating officer David Marchick said in an emailed statement.

The managing director of Biological E. Limited, Mahima Datla expressed her pleasure and said, "This investment will not only help us augment our capacity to produce more COVID-19 vaccines, but also help the global community that has been relentlessly fighting against the spread of the COVID-19 pandemic.”

The release further said that DFC's investment in Biological E. Limited is part of the agency's Global Health and Prosperity Initiative, which is focused on supporting the global response to the COVID-19 pandemic and strengthening health resilience in developing countries.

Image Courtesy: India.com